Cytisinicline has a strong evidence base to support US licensure as a smoking cessation aid. If approved and its effectiveness in clinical practice confirms its clinical trial efficacy, cytisinicline will likely join varenicline and combination nicotine replacement as a first-line smoking cessation treatment option. It may also aid cessation of electronic-cigarette vaping or other nicotine-mediated dependence disorders.
Rigotti et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: